About
Steven A. Elms has been a director of ADMA since 2007 and serves as Chairman of the Board. He is a Managing Partner at Aisling Capital, which he joined in 2000.
He was previously a Principal in the Life Sciences Investment Banking Group of Hambrecht & Quist, where over five years he was involved in more than 60 financing and M&A transactions, and earlier traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. He received a B.A. in Human Biology from Stanford University and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.
Roles
Adma Biologics, Inc.
Chairman of the Board · Current role
2007–present
Hambrecht & Quist
Principal, Life Sciences Investment Banking Group · Involved in over 60 financing and M&A transactions over roughly five years.
—
Donaldson, Lufkin & Jenrette
Mortgage-backed securities trader
—
External Roles
Aisling Capital
Managing Partner
—
Elevation Oncology (Nasdaq: ELEV)
Board of Directors
—
Marker Therapeutics (Nasdaq: MRKR)
Board of Directors
—
Treeline Biosciences
Board of Directors
—
Marker Therapeutics
Board of Directors
—
Director Compensation
FY 2025
Fees earned or paid in cash
$96,250
Stock awards (RSUs)
$174,986
Also at Adma Biologics, Inc.